Skye Bioscience, Inc.
NASDAQSkye Bioscience reports Thursday with short sellers notably less convicted than they were a month ago. Short interest has fallen sharply. The position dropped 20% over the past week alone to 3.8% of the free float — down from roughly 5% in mid-April — suggesting bears who built up around the Phase 2a nimacimab data window have been covering rather than pressing. Borrowing…
Snapshot as of 7 May 2026
Skye Bioscience reports Thursday with short sellers notably less convicted than they were a month ago. Short interest has fallen sharply. The position dropped 20% over the past week alone to 3.8% of the free float —…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for SKYE — free to start on ORTEX.
Sign up for free →Open SKYE on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live SKYE data →